You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
佐力藥業(300181.SZ)半年度淨利潤降20.27%至2751.21萬元
格隆匯 08-21 18:51

格隆匯8月21日丨佐力藥業(300181.SZ)發佈2019年半年度報告,實現營業收入4.29億元,同比增長9.36%;歸屬於上市公司股東的淨利潤2751.21萬元,同比下降20.27%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤2515.18萬元,同比下降16.04%;基本每股收益0.0452元。

公司立足於藥用真菌生物發酵技術生產中藥產品,目前主要從事藥用真菌系列產品、中藥飲片及中藥配方顆粒的研發、生產與銷售。

公司立足於藥用真菌生物發酵技術生產中藥,烏靈系列和百令系列為公司核心產品。烏靈膠囊、靈澤片、百令片進入2018年版國家基藥目錄,在國家推進分級診療的大趨勢下,有利於進一步拓展覆蓋縣級醫院、社區鄉鎮衞生院,滿足基層醫療市場需求。2018年度中國非處方藥生產企業綜合統計排名中,本公司排名第55位;2018年度中國非處方藥產品綜合統計排名(中成藥)中,烏靈膠囊在頭痛失眠類排名中位列第2位,百令片在補益類排名中位列第11位。2018年在中國重點城市公立醫院中成藥終端安神補腦藥產品排名中烏靈膠囊位居首位,佔23.07%。公司積極佈局和拓展中藥飲片、中藥配方顆粒業務,探索精準醫療、細胞免疫治療領域。公司將聚焦主業,整合資源,提升市場優勢,提高在醫藥行業的影響力和地位,實現公司可持續發展。

報告期內,公司主要產品烏靈系列、百令系列銷售收入有所增長,中藥飲片系列產品銷售收入有所下降;同時,為抓住烏靈膠囊等產品進入基藥目錄的機會,加快在基層醫療機構的市場覆蓋,公司適當加大了市場開發投入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account